Early Answers, Better Outcomes: How Cx Precision Medicine Is Rethinking Alzheimer's Diagnosis From the Ground Up

What if the most important moment in Alzheimer's care happened not in a neurologist's office, but at a routine primary care visit? That is the premise behind Cx Precision Medicine's NeuroFirst Memory, a blood-based triage test designed to help primary care physicians quickly determine whether a symptomatic patient's memory concerns warrant specialist referral or can be addressed right where care begins.

In this Health Moonshot Update, StartUp Health co-founder Unity Stoakes speaks with Danguole Altman, CEO of CxPM, about the broken diagnostic pathway that leaves patients waiting years for answers, the science grounding NeuroFirst Memory in one of the largest multi-ethnic neurodegenerative disease datasets ever assembled, and what a smarter triage step could mean for patients, payers, and the future of precision medicine.

🧠 The structural failures driving the 3.5-year diagnostic delay
🩸 How AI plus blood biomarkers power a scalable, primary care-ready triage tool
⏱️ Why the intervention window closes faster than most people realize
💰 The reimbursement strategy that keeps NeuroFirst Memory on the covered side of the line
🔬 A pipeline built for Parkinson's and Alzheimer's subtype diagnostics
🚀 CxPM's Series A and the road to broad clinical launch
🌐 What even a seasoned entrepreneur can learn as a member of the StartUp Health Community